Acorn Biolabs, a personalized regenerative medicine company that offers the world’s first non-invasive, follicle-based, stem cell cryopreservation service and is developing treatments made from a patient’s own cells, today announced that Crystal Muilenburg has joined the company as Chief Commercial Officer. In this newly created role, Crystal will be responsible for commercial strategy and the buildout of the sales and marketing team to prepare the company to launch its first personalized regenerative products to the aesthetics market in the next year.
The company launched its hair-follicle derived, stem cell banking service in Canada and the United States last year. Leveraging these preserved stem cells, Acorn plans to develop a pipeline of personalized products in aesthetics, orthopedics and other markets where stem-cell derived treatments fill an unmet need.
“This is a pivotal time at Acorn as we expand awareness of our unique cryopreservation service and prepare to launch our first commercial product in aesthetics,” said Drew Taylor, MSc, PhD, CEO of Acorn Biolabs. “Crystal’s experience launching and growing brands in aesthetics, as well as several therapeutic categories Acorn is pursuing, will be a tremendous asset as we embark on our next phase of growth.”
“Not just in aesthetics, but in all categories of medicine, personalization is the future,” said Crystal Muilenburg, CCO of Acorn Biolabs. “I’m thrilled to join Acorn at this stage of the company’s journey and to help bring this vision to life.”
Crystal brings nearly 25 years of experience in marketing, corporate communications/PR and operations for global Fortune 500 companies and public start-ups. Most recently, Crystal served on the Board of Elevai Labs (NASDAQ: ELAB), a topical regenerative skin care company. Crystal was Chief Marketing Officer at Evolus (NASDAQ: EOLS) where she led the re-launch of Jeuveau®, a disruptor brand to BOTOX® Cosmetic. Under her leadership, Jeuveau® became the fastest-growing neurotoxin in the United States and one of the top five product launches in aesthetics history. Prior to Evolus, Crystal was Head of Global Strategic Marketing for Sienna Biopharmaceuticals (NASDAQ: SNNA), a clinical-stage medical dermatology company. Crystal also spent more than a decade at Allergan (NYSE: ABBV) in various leadership roles in US and International marketing and communications where she gained significant commercial launch experience with the company’s flagship BOTOX® franchise and leading aesthetics brands.
